Choice of treatment options for metastatic hormone-sensitive prostate cancer
The arsenal of available treatments and treatments for metastatic hormone-sensitive prostate cancer (mHRPC) has increased significantly over the past 5 years. Although androgen-preferential therapy (ADT) remains the mainstay of treatment, the addition of docetaxel, abiraterone, enzalutamide, apaluta...
| Үндсэн зохиолчид: | , , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | Russian |
| Хэвлэсэн: |
Remedium Group LLC
2020-12-01
|
| Цуврал: | Медицинский совет |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.med-sovet.pro/jour/article/view/5941 |